Table 1.
Risk of type 2 diabetes, all-cause mortality, major osteoporotic fracture and dementia in participants initiating fenofibrate compared to those using simvastatin
| Fenofibrate | Simvastatin | |
|---|---|---|
| Incident type 2 diabetes | ||
| Participantsa, n | 1,602 | 6,384 |
| Events, n | 62 | 335 |
| Mean follow-up (years) | 0.93 | 0.94 |
| Rate of event, per 1,000 person-years | 41.4 | 55.9 |
| RD (95% CI), per 1,000 person-years | −14.5 (−26.4 to −2.6) | 0.0 (reference) |
| HR (95% CI) | 0.59 (0.46–0.76) | 1.00 (reference) |
| All-cause mortality | ||
| Participantsb, n | 7,236 | 28,086 |
| Events, n | 73 | 354 |
| Mean follow-up (years) | 0.97 | 0.97 |
| Rate of event, per 1,000 person-years | 10.4 | 13.0 |
| RD (95% CI), per 1,000 person-years | −2.6 (−5.2 to 0.0) | 0.0 (reference) |
| HR (95% CI) | 0.78 (0.60–1.00) | 1.00 (reference) |
| Incident major osteoporotic fracture | ||
| Participantsc, n | 6,749 | 25,923 |
| Events, n | 19 | 120 |
| Mean follow-up (years) | 0.97 | 0.97 |
| Rate of event, per 1,000 person-years | 2.9 | 4.8 |
| RD (95% CI), per 1,000 person-years | −1.9 (−3.4 to −0.3) | 0.0 (reference) |
| HR (95% CI) | 0.51 (0.33–0.81) | 1.00 (reference) |
| Incident dementia | ||
| Participantsd, n | 7,201 | 27,924 |
| Events, n | 12 | 102 |
| Mean follow-up (years) | 0.97 | 0.97 |
| Rate of event, per 1,000 person-years | 1.7 | 3.7 |
| RD (95% CI), per 1,000 person-years | −2.0 (−3.3 to −0.8) | 0.0 (reference) |
| HR (95% CI) | 0.51 (0.29–0.89) | 1.00 (reference) |
RD, rate difference; HR, hazard ratio; 95% CI, 95% confidence interval.
aIncluding participants with pre-diabetes.
bIncluding participants with pre-diabetes and type 2 diabetes.
cIncluding participants with pre-diabetes and type 2 diabetes and excluding those with a history of major osteoporotic fracture.
dIncluding participants with pre-diabetes and type 2 diabetes and excluding those with a history of dementia.